Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs

Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs

Sep 16, 2016
Source URL: https://qa1.novartis.us/news/media-releases/novartis-data-finds-relapsing-ms-patients-gilenya-had-greater-treatment-retention-and-satisfaction-rates-vs-injectable-dmts-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-data-finds-relapsing-ms-patients-gilenya-had-greater-treatment-retention-and-satisfaction-rates-vs-injectable-dmts-0